Medtronic plc is on a recovery trajectory, reporting organic growth in its Cardiovascular, Neuroscience, and Diabetes segments while grappling with a 12% decline in stock value due to unfavorable currency movements and global uncertainties. The company has gained about 400 basis points of market share across 60% of its businesses and anticipates organic revenue growth of 7-8% for fiscal 2022, a revision from earlier estimates. While U.S. revenues remain flat, Medtronic continues to outperform the medical products industry, aiming to return to pre-COVID levels by year-end.
“Medtronic plc · is gaining from the launch of · globally-accepted advanced therapies”
“Medtronic · is affected by · unfavorable currency movement and global economic uncertainties”
“Medtronic · has a Zacks Rank · #3 (Hold)”
“Medtronic · has outperformed · the industry”
“Medtronic · has declined · 12%”
“Medtronic · registered organic growth in · the Cardiovascular, Neuroscience and Diabetes segments”
“Medtronic · gained about · 400 basis points of share”
“Medtronic · has been witnessing · a strong recovery”
“Medtronic · expects to be back to · pre-COVID levels in most of its markets”
“Medtronic · missed · the Zacks Consensus Estimate”
“Medtronic · now expects organic revenue growth of · 7-8%”
“Medtronic · has U.S. revenues that were · flat”